Algorae PharmaceuticalsASX:1AI +10.00% Current Ratio is 18.03 as of Dec. 2025, which is 28% above its 10-year median of 14.11. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Algorae Pharmaceuticals ranks better than 90.19% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Algorae Pharmaceuticals's current ratio for the quarter that ended in Dec. 2025 was 18.03.
Algorae Pharmaceuticals has a current ratio of 18.03. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Algorae Pharmaceuticals's Current Ratio or its related term are showing as below:
ASX:1AI'
s Current Ratio Range Over the Past 10 Years
Min: 3.33 Med: 14.11 Max: 30.86
Current: 18.03
During the past 13 years, Algorae Pharmaceuticals's highest Current Ratio was 30.86. The lowest was 3.33. And the median was 14.11.
ASX:1AI's Current Ratio is ranked better than 90.19% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs ASX:1AI: 18.03
Algorae Pharmaceuticals (ASX:1AI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Algorae Pharmaceuticals Current Ratio Related Terms
Algorae Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:1AI vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Algorae Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Algorae Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Algorae Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Algorae Pharmaceuticals (ASX:1AI) has a Current Ratio of 18.03 as of Dec. 2025. This is 28% above median its historical median of 14.11. Over the past decade, Algorae Pharmaceuticals' Current Ratio has ranged from 3.33 to 30.86. According to the industry distribution chart, Algorae Pharmaceuticals ranks #139 out of 1417 companies in the Biotechnology industry, placing it in the top 9.8%.
Is Algorae Pharmaceuticals' Current Ratio too high?
Algorae Pharmaceuticals' current Current Ratio of 18.03 is 28% above median its 10-year median of 14.11. Over the past 10 years, this metric has ranged from a low of 3.33 to a high of 30.86. The Biotechnology industry median Current Ratio is 3.89. Algorae Pharmaceuticals' value of 18.03 is 363.5% above this industry median. Based on the distribution chart, Algorae Pharmaceuticals ranks #139 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Algorae Pharmaceuticals' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #139 out of 1417 companies for Current Ratio. This places Algorae Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Algorae Pharmaceuticals' value of 18.03 is 363.5% above this benchmark. Historically, Algorae Pharmaceuticals' own Current Ratio has ranged from 3.33 to 30.86 over the past decade. While the company's 10-year median is 14.11 vs. the industry median of 3.89, Algorae Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Algorae Pharmaceuticals's current Current Ratio of 18.03 is 363.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Algorae Pharmaceuticals's current Current Ratio is 18.03, which is 28% above median its own 10-year median of 14.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Current Ratio of 18.03. The current Current Ratio is 18.03, which is 28% above median its 10-year median of 14.11 and 363.5% above the Biotechnology industry median of 3.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Current Ratio is 18.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:1AI has been successfully added to your 